

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ANCLIFF, Rachael *et al.*  
Serial No.: 10/531,758  
Filing Date: April 14, 2005

Group Art Unit: 1624  
Examiner: COLEMAN, Brenda Libby

Confirmation No.: 5647  
Attorney Docket No.: P33126USw

Title: *Substituted Piperazines (1,4) Diazepines, and 2,5-Diazabicyclo (2.2.1) Heptanes as Histamine H1 and/or H3 Antagonists or Histamine H3 Reverse Antagonists*

---

Okay to Enter

/B.C. / 9/30/09

MAIL STOP ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PETITION TO CORRECT INVENTORSHIP UNDER 37 CFR §1.48(b)**

This Petition is filed under 37 CFR §1.48(b) with the payment of the Issue Fee. In this application, fewer inventors should be listed due to amendment or cancellation of claims. The correct inventors were named in this non-provisional application as filed. Prosecution of this application resulted in the amendment or cancellation of the claims, such that fewer than all of the currently-named inventors are the actual inventors of the invention being claimed.

Applicants hereby request that the inventorship be amended as follows:

As originally-filed, the following individuals were listed as inventors:

ANCLIFF, Rachael  
ELDRED, Colin David  
FOGDEN, Yvonne C.  
HANCOCK, Ashley Paul  
HEIGHTMAN, Thomas Daniel  
HOBBS, Heather  
HODGSON, Simon Teanby  
LINDON, Matthew J.  
WILSON, David Matthew

Please ***delete*** the following individuals from the list of inventors, as these individuals' contributions are no longer being claimed in this application: